Alzheimer’s disease (https://www.simulations-plus.com/wp-admin/post.php?post=35654&action=editAD), a neurodegenerative condition previously known to affect the older population, is also now seen in younger individuals.
Creating Quality by Committing to Compliance in Clinical Research
In the highly regulated world of clinical research, compliance is an ongoing concern, but can be viewed as an annoying and costly item to check off a regulatory to-do list.
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives
Rational drug use in special populations is a clinical problem that doctors and pharma-cists must consider seriously.
Log D7.4 and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity
The emergence of new synthetic cannabinoid receptor agonists (SCRAs) onto the illicit drugs market continues to cause harm, and the overall availability of physicochemical and pharmacokinetic data for new psychoactive substances is lacking.
QSP Ulcerative Colitis (UC) Model Flyer
Quantitative Systems Pharmacology (QSP)
Ulcerative Colitis Model
QSP Systemic Lupus Erythematosus (SLE) Model Flyer
Quantitative Systems Pharmacology (QSP)
Systemic Lupus Erythematosus Model
QSP Rheumatoid Arthritis (RA) Model Flyer
Quantitative Systems Pharmacology (QSP)
Rheumatoid Arthritis Model
QSP Psoriatic Arthritis Model Flyer
Quantitative Systems Pharmacology (QSP)
Psoriatic Arthritis Model
QSP Psoriasis Model Flyer
Quantitative Systems Pharmacology (QSP)
Psoriasis Model
QSP Crohn’s Disease (CD) Model Flyer
Quantitative Systems Pharmacology (QSP)
Crohn’s Disease (CD) Model
QSP Atopic dermatitis Model Flyer
Quantitative Systems Pharmacology (QSP)
Atopic dermatitis Model
December 2023 News/Events
Fully Power Your First-in-Human Predictions
Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives
Over the past few decades, physiologically based biopharmaceutics modeling (PBBM) has demonstrated its utility in both new drug and generic product development.
In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
The prediction of intestinal absorption of various drugs based on computer simulations has been a reality.
Cross species extrapolation of the disruption of thyroid hormone synthesis by oxyfluorfen using in vitro data, physiologically based pharmacokinetic (PBPK), and thyroid hormone kinetics models
The thyroid hormones play key roles in physiological processes such as regulation of the metabolic and cardiac systems as well as the development of the brain and surrounding sympathetic nervous system.
How to Select Your First-in-Human Modeling and Simulation Software Platform
Determining appropriate dosage for your first in human (FIH) clinical trials is critical.
Quantitative Systems Toxicology (QST) Modeling Using a New Virtual Population in BIOLOGXsym Offers Mechanistic Insights Into Bile Acid-mediated Biologics-induced Liver Injury (BILI) Upon Cimaglermin Alfa (GGF2) Administration
Biopharmaceuticals are increasingly used to treat various medical conditions, but BILI events can end...
Advancing the Multi-Targeted Mechanisms of Action of a Mitochondrial Activator (AXA1125) for Treating NASH Using a Quantitative Systems Pharmacology Model
Patients with non-alcoholic steatohepatitis (NASH) do not currently have options for pharmaceutical...
SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer’s disease
The risk of developing Alzheimer's disease is associated with genes involved in microglial function.
